Biosensors for the Detection of Minimal Residual Disease in Leukaemia

Back to search results

Monitoring of minimal residual disease (MRD) during and following combination chemotherapy is one of the most accurate methods of predicting disease outcome in acute leukaemia. However, current techniques rely on sampling from the patient's bone marrow, with its associated morbidity. Circulating tumour DNA can act as a surrogate for the whole cancer cell genome, and can provide highly sensitive and specific cancer diagnostic and prognostic information. This interdisciplinary project aims to develop highly accurate and sensitive biosensors for MRD monitoring in the peripheral blood of acute leukaemia patients, and its successful implementation will have a significant impact on human health.

Apply Now
Supervisory team

Women's and Children's Health


Women's and Children's Health

Apply Now

Please start your application by taking the self assessment. Download the editable MS Word version or download the non-editable PDF version (best for Mac or mobile devices). Once the self assessment form is completed, save as a PDF and upload along with your application.

One file only.
50 MB limit.
Allowed types: gif jpg png bmp eps tif pict psd txt rtf html odf pdf doc docx ppt pptx xls xlsx xml avi mov mp3 ogg wav bz2 dmg gz jar rar sit svg tar zip.
If you have not done so, please complete the self assessment PDF as noted above.